Adicet Bio (ACET) Q2 Loss Widens 3%
Adicet Bio (NASDAQ:ACET), a biotechnology company focused on gamma delta T cell therapies for autoimmune diseases and cancer, reported its second quarter 2025 earnings on August 7, 2025. No revenue was recognized as the company remains a precommercial stage biotech. The company continues to advance its clinical programs and has implemented cost reductions to extend its operational runway. The quarter showed progress in clinical development, pipeline prioritization, increased research investment, and a leaner operating structure, but the financials highlight ongoing dependence on future clinical milestones and capital resources.
Source: Analyst estimates for the quarter provided by FactSet.
Adicet Bio is focused on discovering and developing off-the-shelf, allogeneic gamma delta T cell therapies aimed at treating both autoimmune diseases and cancer. These therapies are designed as one-time treatments and seek to differentiate the company in the competitive field of cell therapy by offering the potential for broad tissue targeting and reduced side effects.
Source Fool.com
